[go: up one dir, main page]

EP2672959A1 - Composition de granulés comportant du tadalafil et un délitant - Google Patents

Composition de granulés comportant du tadalafil et un délitant

Info

Publication number
EP2672959A1
EP2672959A1 EP11703449.6A EP11703449A EP2672959A1 EP 2672959 A1 EP2672959 A1 EP 2672959A1 EP 11703449 A EP11703449 A EP 11703449A EP 2672959 A1 EP2672959 A1 EP 2672959A1
Authority
EP
European Patent Office
Prior art keywords
tadalafil
granulate
dosage form
superdisintegrant
croscarmellose sodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11703449.6A
Other languages
German (de)
English (en)
Inventor
Marta VIVANCOS MARTINEZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synthon BV
Original Assignee
Synthon BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthon BV filed Critical Synthon BV
Publication of EP2672959A1 publication Critical patent/EP2672959A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin

Definitions

  • the present invention relates to a co-granulate comprising tadalafil and a
  • superdisintegrant advantageously croscarmellose sodium
  • CIALIS® is a known pharmaceutically active compound, which is marketed, e.g., under brand name CIALIS®, for the treatment of erectile dysfunction and pulmonary arterial hypertension.
  • the marketed product is a film-coated tablet for oral administration comprising 2.5, 5, 10 or 20 mg of the active substance.
  • Inactive ingredients in CIALIS® are lactose monohydrate, croscarmellose sodium, hydroxypropylcellulose, microcrystalline cellulose, sodium laurylsulfate and magnesium stearate.
  • Tadalafil and its pharmaceutical compositions have been disclosed, e.g., in WO 95/19978 and WO 00/66099.
  • tadalafil is in a certain aspect a follow-up product to the well known compound sildenafil (Viagra). Its main advantage is longer duration of action and minimized potential for side effects such as vision abnormalities.
  • tadalafil One possibility of improving the dissolution rate of tadalafil from solid pharmaceutical compositions is to use the active ingredient with low average particle size.
  • the patent applications WO 01/08688 and WO 01/08686 disclose a population of tadalafil particles characterized by an average particle size (expressed as d(0.9)) less than 40 ⁇ . Such particulated form of tadalafil may exhibit better dissolution from pharmaceutical
  • tadalafil is thereby finely dispersed in the carrier, which may result in improved dissolution due to enhanced surface area of the drug substance.
  • solid dispersions comprising tadalafil have been disclosed, e.g., in WO 96/38131.
  • Molecular dispersions of tadalafil in a polymeric carrier have been disclosed, e.g., in WO 2009/000493.
  • a pharmaceutical composition comprising a combination of tadalafil and starch has been disclosed in WO 2008/134557.
  • An adsorbate of tadalafil on the surface of silica has been disclosed in EP 2238979.
  • compositions have been disclosed, e.g., in WO 00/20033, WO 01/41807, WO 2007/002125 or WO 2008/005039.
  • the present invention relates to pharmaceutical compositions comprising a granulated product comprising tadalafil and a superdisintegrant, preferably croscarmellose sodium.
  • the present invention provides a co-granulate, preferably a free-flowing co-granulate, comprising tadalafil, a superdisintegrant, and, preferably, at least one binder and/or filler.
  • a preferred superdisintegrant is croscarmellose sodium.
  • the weight ratio between croscarmellose sodium and tadalafil is equal to or higher than 5 : 1.
  • the present invention provides a process comprising a step of aqueous granulation of tadalafil with a superdisintegrant, e.g. croscarmellose sodium, preferably in the presence of a binder, followed by drying the resulting granulate.
  • a superdisintegrant e.g. croscarmellose sodium
  • the tadalafil starting material for making the co-granulate comprises a population of tadalafil particles characterized by a particle size d(0.9) > 40 ⁇ .
  • the present invention provides a pharmaceutical composition comprising the co-granulate as defined above and at least one pharmaceutically acceptable excipient.
  • the present invention provides a process for making a tadalafil- comprising pharmaceutical composition, comprising a step of providing a co-granulate comprising tadalafil and a superdisintegrant, preferably croscarmellose sodium, followed by a step of dry mixing the above co-granulate with at least one pharmaceutically acceptable excipient.
  • the present invention provides a pharmaceutical oral dosage form comprising tadalafil, preferably a compressed dosage form, comprising a dose of the pharmaceutical composition as defined above.
  • the dosage form exhibits a dissolution rate of at least about 70 wt% within about 15 min when tested by the Ph. Eur. paddle method in 1000 ml of an aqueous medium containing 0.35% of SLS with the paddle rotating at a speed of 50 rpm.
  • the present invention provides a process for making a pharmaceutical oral dosage form comprising tadalafil, comprising the steps of:
  • composition and/or dosage form preferably comprises from 2 to 10% of tadalafil (w/w).
  • the dosage form preferably comprises from 1 to 50 mg of tadalafil.
  • the invention relates to the use of the co-granulate of tadalafil with croscarmellose sodium, preferably in free-flowing particulate form, in medicine, in particular in the treatment of erectile dysfunction and pulmonary arterial hypertension.
  • the present invention relates to the enhancement of the inherently poor dissolution of tadalafil from solid pharmaceutical compositions by formulating tadalafil into a co-granulate with a superdisintegrant, preferably with croscarmellose sodium, and, optionally, a binder.
  • the "superdisintegrant" in our application is a conventionally used term in the pharmaceutical industry and refers to a compound, which exhibits a rapid and a high degree of swelling when in contact with saliva or intestinal fluid.
  • Typical examples which are also subject of our invention, are modified celluloses, e.g. croscarmellose sodium or low substituted hydroxypropyl cellulose, cross-linked polymers, e.g. crospovidone, or modified starches, e.g. sodium starch glycolate.
  • Croscarmellose sodium is the sodium salt of a cross-linked, partly O- (carboxymethylated) cellulose. It is a well known and well defined excipient in the pharmaceutical industry, typically useful as a disintegrant. It is commercially available under various brand names. For more details about this excipient, see ,e.g., Arthur H. Kibbe (Ed.), Handbook of Pharmaceutical Excipients, Third Edition 2000, p. 160-162).
  • the present invention typically provides a co-granulate of tadalafil with croscarmellose sodium.
  • the weight ratio between croscarmellose sodium and tadalafil in the co- granulate is equal to or higher than 5 : 1.
  • This co-granulate preferably in amounts, which assure the final concentration of tadalafil therein of between 2 to 10% (w/w), may be formulated in solid pharmaceutical compositions, e.g. by a dry mixing with extragranular excipients.
  • This inventive solution is based on the finding that dissolution of the inherently poorly soluble tadalafil may be sufficiently increased by this co-granulation, when comparing it with a composition, wherein croscarmellose sodium has been formulated into a tadalafil- comprising solid pharmaceutical composition in conventional concentrations (0.5-5%) and without pre-granulation with tadalafil. Furthermore, it was found that it is not necessary to provide a population of tadalafil particles of an average particles size (when expressed by the d(0.9) value) of less than 40 ⁇ .
  • the dissolution rate can be, in general, enhanced by increasing the surface area of the drug by micronization
  • the micronized particles have a tendency to agglomerate and this effect can result in a decreased effective surface for dissolution.
  • the inventor speculates that the granulation causes deposition of the drug upon the surface of the hydrophilic and strongly swelling superdisintegrant. Once digested, the superdisintegrant discomposes the medicament delivering a fine suspension of drug particles, which prevents agglomeration and improves the dissolution.
  • tadalafil substance having an average particle size d(0.9) higher than 40 ⁇ , e.g. tadalafil directly produced by a chemical synthesis.
  • d(0.9)value in association with a number means that the size of 90% of the particles of the population are less than or equal to the size expressed by that number when measured by a light scattering method.
  • the co-granulate of the invention may also comprise at least one binder, for instance microcrystalline cellulose, methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, polyvinylpyrrolidone, copovidone, sodium alginate etc.
  • the binder may improve physical properties of the co-granulate, particularly it may assure that the co-granulate is obtained as a free-flowing particulate material with good handling properties.
  • the co-granulate may optionally comprise one or more inert fillers/diluents, e.g., lactose, lactose monohydrate, mannitol, sorbitol, microcrystalline cellulose, dextrates, dextrins, dextrose, fructose, lactitol, maltitol, maltodextrins, maltose, calcium phosphates, xylitol, which assure a proper final concentration of tadalafil in the final composition.
  • inert fillers/diluents e.g., lactose, lactose monohydrate, mannitol, sorbitol, microcrystalline cellulose, dextrates, dextrins, dextrose, fructose, lactitol, maltitol, maltodextrins, maltose, calcium phosphates, xylitol, which assure a proper final concentration of
  • the co-granulate of the invention does not comprise starch.
  • the co-granulate of the present invention is advantageously prepared by a wet granulation process.
  • water may be advantageously used as the granulation liquid in the process of the invention despite the prejudice that superdisintegrants are sensitive to water.
  • water does not substantially affect the disintegration ability, rather it aids in assuring a uniform content of tadalafil within the granulate.
  • organic solvents e.g. ethanol
  • granulation liquids e.g.
  • a useful process of making the co-granulate comprises the following steps:
  • the mixing and granulating is typically performed with the same equipment, at a speed of about 100 to 200 rpm.
  • Croscarmellose sodium and tadalafil are preferably mixed in the weight ratio equal to or higher than 5 : 1.
  • the relative weight amount of the binder is typically between 1/5 to 1/10 of the weight of tadalafil.
  • the relative weight amount of water is typically 10 to 50 weight % in respect to the solid material.
  • the drying step is performed in fluid bed equipment, at a temperature of about 40°C to about 60°C, typically at about 50°C.
  • the dry co-granulate may be milled and/or sieved on a suitable
  • the co-granulate of the present invention and/or the co-granulate made by the above process may be formulated into solid pharmaceutical compositions, preferably into tablet compositions, by combining it with at least one extragranular pharmaceutically acceptable excipient.
  • a typical process of such formulation comprises a step of providing the above co- granulate followed by a step of dry mixing it with at least one pharmaceutically acceptable excipient. As rapid dissolution of tadalafil from the composition is therapeutically
  • composition typically does not comprise any excipient serving as a release- controlling agent.
  • excipients typically comprise:
  • a] at least one water soluble or water insoluble filler/binder are, without any limitation, lactose, lactose monohydrate, mannitol, sorbitol, microcrystalline cellulose, methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, dextrates, dextrins, dextrose, fructose, lactitol, maltitol, maltodextrins, maltose, calcium phosphates, xylitol, starch, modified starch, polyvinylpyrrolidone, copovidone, sodium alginate, etc.
  • the examples are, without any limitation, starches, cross-linked celluloses, or cross-linked polymers such as starch, modified starch,
  • croscarmellose sodium crospovidone
  • sodium starch glycolate carboxymethylcellulose calcium, carboxymethylcellulose sodium, colloidal silicon dioxide, guar gum, magnesium aluminium silicate, methylcellulose, polacrilin potassium, sodium alginate, etc.
  • c at least one lubricant.
  • the examples are, without any limitation, talc, magnesium stearate, calcium stearate, stearic acid, hydrogenated vegetable oils, palmitic acid, carnauba wax, mineral oil, sodium stearyl fumarate, polyethylene glycol, etc.
  • the relative amount of tadalafil in the solid pharmaceutical composition is typically from about 2 to about 10 weight %. Accordingly, the relative amount of croscarmellose sodium in the composition is typically from about 10 to 50%, based on the total weight of the composition.
  • composition of the present invention is advantageously formulated into a dosage form; such dosage form comprises a desired dose of the
  • the dosage form is a compressed dosage form, which is typically a tablet.
  • the compressed dosage form is formulated by a process of direct compression. This process comprises adjusting the composition to portions - dose units - comprising a therapeutic amount of the active substance and compressing the doses of the composition to tablets on a suitable tablet press.
  • the tablets should have a suitable hardness in order to obtain tablets with a friability below 0.5% preferably below 0.1%.
  • the typical hardness of the tablets is 75N.
  • the dosage form typically comprises from 1 to 50 mg of tadalafil, preferably 2.5, 5, 10 or 20 mg of tadalafil.
  • the compressed dosage form preferably exhibits a dissolution rate which is characterized by a dissolution of more than 70 wt% of tadalafil in 15 min when a sample of the composition is tested by a Ph. Eur. paddle method in 1000 ml of an aqueous medium containing 0.35% of sodium laurylsulfate with the paddle rotating at a speed of 50 rpm.
  • the tablets may be optionally further coated by a film-coat.
  • the coating serves generally for cosmetic purposes.
  • the coating material typically has no influence on the release rate, except of an inherent short initial delay in dissolution due to the time necessary to dissolve the coat.
  • the coating may be selected from amongst one or more of those suitable coating materials known in the art. Coating may be performed by applying one or more film forming polymers, with or without other pharmaceutically inert excipients, as a solution/suspension. Coating is done using any conventional coating technique known in the art, such as spray coating in a conventional coating pan or fluidized bed processor; or dip coating.
  • the co-granulate of tadalafil with a superdisintegrant which advantageously is croscarmellose sodium, typically in a weight ratio of croscarmellose sodium and tadalafil equal to or higher than 5 : 1, as well as pharmaceutical compositions and dosage forms comprising it are useful in medicine, specifically for the treatment of diseases and conditions known to be treated with tadalafil.
  • these conditions include erectile dysfunction and pulmonary arterial hypertension, but are not limited thereto.
  • the present invention provides a method of treatment, particularly that of erectile dysfunction or pulmonary arterial hypertension, comprising orally administering to a patient in need thereof a solid pharmaceutical composition comprising a therapeutical amount of tadalafil within a co-granulate with a superdisintegrant, advantageously croscarmellose sodium, typically in a weight ratio of croscarmellose sodium and tadalafil equal to or higher than 5 : 1.
  • Example 1 Pharmaceutical tablet comprising tadalafil and croscarmellose sodium granulate
  • hydroxypropylcellulose and aerosil was made in a high shear mixer for 5 min. After that, a 20% of water w/w of powder was poured onto the powder and mixed at 150 rpm to obtain a granulate. The granulate was dried in a fluid bed equipment until a loss on drying below 2% was obtained.
  • the resulting granulate was sieved manually through a 1 mm sieve and mixed with microcrystalline cellulose and crospovidone for 15 min. Finally, Mg stearate was added to the blend and mixed for 5 min.
  • the lubricated blend was compressed in an excentric press machine at a compression force of approx. 13 kN.
  • the resulting tablets showed a hardness of 74 N, a disintegration time ⁇ 2 min and a friability of 0.2%.

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP11703449.6A 2011-02-10 2011-02-10 Composition de granulés comportant du tadalafil et un délitant Withdrawn EP2672959A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2011/051963 WO2012107090A1 (fr) 2011-02-10 2011-02-10 Composition de granulés comportant du tadalafil et un délitant

Publications (1)

Publication Number Publication Date
EP2672959A1 true EP2672959A1 (fr) 2013-12-18

Family

ID=44474983

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11703449.6A Withdrawn EP2672959A1 (fr) 2011-02-10 2011-02-10 Composition de granulés comportant du tadalafil et un délitant

Country Status (2)

Country Link
EP (1) EP2672959A1 (fr)
WO (1) WO2012107090A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015000853A1 (fr) * 2013-07-05 2015-01-08 Synthon B.V. Composition pharmaceutique comprenant une dispersion solide de tadalafil
KR101663238B1 (ko) * 2013-11-15 2016-10-14 한미약품 주식회사 타다라필 및 암로디핀을 포함하는 복합 고형 제제
CN109157520B (zh) * 2018-09-07 2021-04-02 苏州科技城医院 他达拉非片剂及其制备方法
CN119112817A (zh) * 2024-08-20 2024-12-13 武汉九珑人福药业有限责任公司 一种他达拉非片及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
GB9511220D0 (en) 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions
US6548490B1 (en) 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
WO2000020033A1 (fr) 1998-10-05 2000-04-13 Eisai Co., Ltd. Comprimes se delitant immediatement dans la cavite buccale
MXPA00003997A (es) 1999-04-30 2002-03-08 Lilly Icos Llc Articulos de fabricacion.
WO2001008686A1 (fr) 1999-08-03 2001-02-08 Lilly Icos Llc Compositions pharmaceutiques a base de beta-carboline
UA71629C2 (en) 1999-08-03 2004-12-15 Lilli Icos Llc Composition containing free drug particulate form of ?-carboline (variants), method for its manufacture (variants), and method for treating sexual dysfunction
RS52945B (sr) * 2004-05-11 2014-02-28 Emotional Brain B.V. Farmaceutske formulacije i njihova primena u lečenju ženske seksualne disfunkcije
ES2624585T3 (es) * 2004-05-28 2017-07-17 Imaginot Pty Ltd. Sistema de suministro de compuesto terapéutico oral
CN104083342A (zh) 2004-12-31 2014-10-08 伊休蒂卡有限公司 纳米微粒组合物及其合成方法
MX2008000087A (es) 2005-06-23 2008-03-18 Schering Corp Formulaciones orales rapidamente absorbentes de inhibidores de la fosfodiesterasa 5.
CA2622200A1 (fr) 2005-09-13 2007-03-22 Elan Pharma International, Limited Formulations nanoparticulaires de tadalafil
EP2054042B8 (fr) 2006-06-30 2020-06-10 iCeutica Pty Ltd Procédés de préparation de composés biologiquement actifs sous forme de nanoparticules
BRPI0621852A2 (pt) 2006-07-07 2011-12-20 Teva Pharma compostos sólidos consistindo de tadalafil e pelo menos um veìculo
US20090098211A1 (en) 2007-04-25 2009-04-16 Ilan Zalit Solid dosage forms
DE102007028869A1 (de) 2007-06-22 2008-12-24 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
MX2010010383A (es) * 2008-04-01 2010-12-14 Ocean 1 806 Llc Formulaciones orodispersables de inhibidores de fosfodiesterasa-5 (pde-5).
EP2238979A1 (fr) 2009-04-06 2010-10-13 LEK Pharmaceuticals d.d. Ingrédient pharmaceutique actif absorbé sur un support solide

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2012107090A1 *

Also Published As

Publication number Publication date
WO2012107090A1 (fr) 2012-08-16

Similar Documents

Publication Publication Date Title
JP5835883B2 (ja) 被覆錠剤製剤
JP5714492B2 (ja) 粒状体、それらの調製方法、およびそれらを含む医薬品
EP2209501B1 (fr) Composition de Zibotentane comprenant du mannitol et de la cellulose microcristalline
CA2843138C (fr) Nouvelles formulations de (trimethoxyphenylamino)pyrimidinyle
WO2009084041A2 (fr) Compositions pharmaceutiques de dexibuprofène
EP2672959A1 (fr) Composition de granulés comportant du tadalafil et un délitant
EP2701689B1 (fr) Compositions pharmaceutiques de raltégravir, procédés de préparation et utilisation de celles-ci
JP2017523149A (ja) エドキサバンの医薬組成物
TW201818936A (zh) 一種吡啶酮類衍生物醫藥組成物及其製備方法
CA2599649C (fr) Formulations medicamenteuses ayant une biodisponibilite controlee
WO2012107541A1 (fr) Composition pharmaceutique comprenant du tadalafil et une cyclodextrine
WO2012107092A1 (fr) Composition pharmaceutique comportant du tadalafil et une cyclodextrine
EP3500246A1 (fr) Formulation de comprimé antiparkinsonien à profil de dissolution amélioré
US11260055B2 (en) Oral pharmaceutical composition of lurasidone and preparation thereof
JP6199922B2 (ja) 化学的な安定性が向上したイルベサルタン含有錠剤
WO2019134940A1 (fr) Compositions pharmaceutiques à libération immédiate contenant un sel de lysine de kétoprofène
EP4401708A1 (fr) Composition pharmaceutique d'acide bempédoïque
EP2672960A1 (fr) Composition pharmaceutique comprenant du tadalafil et une cyclodextrine
WO2019030773A1 (fr) Compositions de diclofénac à faible dose
JP2004091373A (ja) 分解に対する安定性及び含量均一性に優れたメシル酸ペルゴリド含有製剤
HK1143095B (en) Zibotentan composition containing mannitol and microcrystalline cellulose
TW201444588A (zh) 含有甲磺酸伊馬替尼的顆粒、包含所述顆粒的快速釋放口服錠劑組成物及其製備方法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130910

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20160211

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160622